Citius Pharmaceuticals, Inc. (CTXR) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CTXR Revenue Growth
CTXR Revenue Analysis (2014–2025)
As of May 8, 2026, Citius Pharmaceuticals, Inc. (CTXR) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, CTXR's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including NKTR (-43.9% YoY), HALO (+37.6% YoY), and PRGO (-3.6% YoY), CTXR has underperformed the peer group in terms of revenue growth. Compare CTXR vs NKTR →
CTXR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CTXRCurrent | $0 | -100.0% | - | - | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 PAHC | $1.3B | +32.4% | +10.1% | 8.5% | |
 ETON | $80M | +104.9% | +359.6% | -1.1% |
CTXR Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-214,250 | - | $-38,525,608 | - |
| 2024 | $0 | - | $-209,611 | - | $-41,995,681 | - |
| 2023 | $0 | - | $-194,316 | - | $-36,732,018 | - |
| 2022 | $0 | - | $-179,677 | - | $-33,316,045 | - |
| 2021 | $0 | - | $-164,868 | - | $-23,531,894 | - |
| 2020 | $0 | - | $-152,364 | - | $-17,710,685 | - |
| 2019 | $0 | - | $-893 | - | $-15,598,361 | - |
| 2018 | $0 | - | $-1,753 | - | $-13,789,143 | - |
| 2017 | $0 | - | $-2,632 | - | $-9,986,311 | - |
| 2016 | $0 | - | $-1,343 | - | $-7,449,291 | - |
See CTXR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTXR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CTXR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCTXR — Frequently Asked Questions
Quick answers to the most common questions about buying CTXR stock.
Is CTXR's revenue growth accelerating or slowing?
CTXR revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $0.00. This reverses the prior growth trend.
What is CTXR's long-term revenue growth rate?
Citius Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is CTXR's revenue distributed by segment?
CTXR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.